update - Kaleo wants all patients to have access to Auvi-Q, regardless of insurance coverage

Kaleo set to relaunch withdrawn Epipen rival Auvi-Q next year

By Gareth Macdonald contact

- Last updated on GMT

Kaleo set to relaunch withdrawn Epipen rival Auvi-Q next year

Related tags: Asthma, Generic drug

Kaleo has said it will relaunch Auvi-Q (epinephrine injection) a year after a recall by licensee Sanofi removed the Epipen rival from the market.

The US firm announced​ it would relaunch Auvi-Q early next year. The product – which is used to treat severe allergic reactions – was recalled last November​ over concerns it could potentially deliver the incorrect dose.

Sanofi handed back rights to the product to Kaleo in February​ and terminated a co-marketing deal it had with PDL Biopharma.

Kaleo also said it had taken over production from Sanofi, adding that it conducted “a thorough manufacturing assessment and invested in new technology and quality systems to ensure accurate, reliable and consistent delivery from the product.​”

Epipen rival

Auvi-Q is a rival for Mylan NV’s EpiPen, the price of which has increased dramatically in recent years.

According to a House Committee on Oversight and Government Reform hearing in September​ Mylan’s Epipen increased 500 percent in the last decade, rising from $100 to more than $600.

Kaleo said it “is aware of the epinephrine auto-injector access and affordability challenges confronting patients” ​adding that it is working with various stakeholders to ensure that “all patients regardless of insurance coverage, have affordable access to Auvi-Q​.”

Spokesman Sam Schwartz declined to say how much Kaleo will charge for Auvi-Q, b ut did say "our goal is that any patient who needs an epinephrine auto-injector, regardless of insurance coverage, should have affordable access to AUVI-Q​." 

Competition

Kaleo may not be the only company to launch an Epipen rival.

When the US FDA rejected a generic version of the product developed by Teva in February​, the firm said it “expects that its epinephrine product will be significantly delayed and that any launch will not take place before 2017​.”

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers